Medication pain management in the elderly: Unique and underutilized analgesic treatment options

Clinical Therapeutics

Volumn 35, Issue 11, 2013, Pages 1669-1689

  Atkinson, Timothy J ^a   Fudin, Jeffrey ^a,b,c,d   Pandula, Abhinetri ^a,e   Mirza, Maira ^c  

^a STRATTON VA MEDICAL CENTER   (United States)

^b American Academy of Pain Management   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e ALBANY MEDICAL CENTER   (United States)

Author keywords

analgesia; buprenorphine transdermal; elderly; levorphanol; opioids; pain management; tapentadol; topical NSAIDs

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CORTICOSTEROID; DEXTROMETHORPHAN; DEXTROMETHORPHAN PLUS MORPHINE; DEXTROPROPOXYPHENE; DEXTRORPHAN; DICLOFENAC; DICLOFENAC EPOLAMINE; DULOXETINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; KETAMINE; LEVOMETHORPHAN; LEVORPHANOL; MEMANTINE; METHADONE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; TAPENTADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

AGED; ANALGESIA; APPLICATION SITE BURNING; APPLICATION SITE PRURITUS; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CONSTIPATION; DIABETIC NEUROPATHY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DIZZINESS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSPHORIA; EUPHORIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GERIATRIC CARE; GERIATRIC PATIENT; HEADACHE; HEART ARRHYTHMIA; HUMAN; LOW BACK PAIN; MEDICATION COMPLIANCE; MENTAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; POLYPHARMACY; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VOMITING; XEROPHTHALMIA; XEROSTOMIA;

ANALGESIA; BUPRENORPHINE TRANSDERMAL; ELDERLY; LEVORPHANOL; OPIOIDS; PAIN MANAGEMENT; TAPENTADOL; TOPICAL NSAIDS;

AGED; AGED, 80 AND OVER; AGING; ANALGESICS; CLINICAL TRIALS AS TOPIC; HUMANS; PAIN; PAIN MANAGEMENT;

EID: 84888012468     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.008     Document Type: Review

References (131)

1. US Dept of Health and Human Services, Administration of Aging. A profile of older Americans. http://www.aoa.gov/Aging-Statistics/Profile/2011/4.aspx. Accessed July 17, 2013.
2. US Census. Table 102. Expectations of Life at Birth, 1970 to 2006, and Projections from 2010 to 2020. http://www.census.gov/compendia/statab/2010/ tables/10s0102.pdf. Accessed July 17, 2013.
3. American Geriatric Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons J Am Geriatr Soc 57 2009 1331 1346
4. T. Dharmarajan, and J. Ugalino The aging process. Geriatric Medicine Board review manual Geriatr Med Volume 1 Part 1 2000
5. S. Maguire, and B. Slater Physiology of ageing Anesth Intens Care Med 11 2013 290 292
6. B. North, and D. Sinclair The intersection between aging and cardiovascular disease Circ Res 110 2012 1097 1108
7. V. Hernandez, T. Booth, and C. Murray Brain white matter damage in aging and cognitive ability in youth and older age Neurobiol Aging 13 2013 245 250
8. Z. Karam, and J. Tuazon Anatomic and physiological changes of the aging kidney Clin Geriatr Med 3 2013 555 564
9. D. Budnitz, D. Pollock, and K. Weidenbach National surveillance of emergency department visits for outpatient adverse drug events JAMA 296 2006 1858 1866
10. Institute of Medicine. Relieving pain in America: A blueprint for transforming prevention, care, education, and research. http://www.iom.edu/~/ media/Files/Report%20Files/2011/Relieving-Pain-in-America-A-Blueprint-for- Transforming-Prevention-Care-Education-Research/ Pain%20Research%202011%20Report%20Brief.pdf. Accessed June 13, 2013.
11. C. Heyneman, C. Lawless-Liday, and G. Wall Oral versus topical NSAIDs in rheumatic diseases: a comparison Drugs 60 2000 555 574
12. Coxib and traditional NSAID Trialists' (CNT) Collaboration N. Bhala, J. Emberson, and A. Merhi Vascular and upper gastrointestinal effects of non-steroidal inflammatory drugs: meta-analyses of individual participant data from randomised trials Lancet 382 2013 769 779
13. P. Arnstein Evolution of topical NSAIDS in the guidelines for treatment of osteoarthritis in elderly patients Drugs Aging 29 2012 523 531
14. W. Zhang, G. Nuki, and R.W. Moskowitz OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009 Osteoarthritis Cartilage 18 2010 476 499
15. C. Durand, A. Alhammad, and K. Willett Practical considerations for optimal transdermal drug delivery Am J Health Syst Pharm 69 2012 116 124
16. V. Skoutakis, C. Carter, and T. Mickle Review of diclofenac and evaluation of its place in therapy as a nonsteroidal anti-inflammatory agent Drug Intell Clin Pharm 22 1988 850 859
17. King Pharmaceuticals. Flector (diclofenac epolamine) patch. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f103f7e8-1253-43cb-9667- cd0d8f4d5500#nlm34084-4. Accessed June 3, 2013.
18. D. Lionberger, A. Lanzarotti, and L. Pierchala Analgesic efficacy and safety of diclofenac epolamine topical patch (Flector patch) by location of injury in trials of acute pain: a pooled analysis of 5 trials. J Appl Res 10 2010 98 108
19. P. Bruhlman, F. de Vathaire, and R. Dreiser Short term treatment with diclofenac epolamine plaster in patients with symptomatic knee osteoarthritis: pooled analysis of two randomized clinical studies Curr Med Res Opin 22 2006 2429 2438
20. P. Jenoure, A. Rostan, and G. Gremion Multicentre, double-blind controlled clinical study on the efficacy of diclofenac epolamine-Tissugel plaster in patients with epicondylitis Med Sport (Roma) 50 1997 285 592
21. B. McCarberg, and C. Argoff Topical diclofenac epolamine patch 1.3% for the treatment of acute pain caused by soft tissue injury Int J Clin Pract 46 2010 1546 1553
22. B. Petersen, and S. Rovati Diclofenac epolamine (Flector) patch: evidence for topical activity Clin Drug Invest 29 2009 1 9
23. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Flector patch: clinical pharmacology and biopharmaceutics reviews. http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2007/021234s000-ClinPharmR.pdf. Accessed June 3, 2013.
24. A. Fini, G. Fazio, and I. Rapaport Diclofenac/N-(2-hydroxyethyl) pyrrolidine: a new salt for an old drug Drugs Exp Clin Res 19 1993 81 88
25. N. Moore Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety Clin Drug Invest 27 2007 163 195
26. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Flector patch: medical review part 1. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2007/021234s000-MedR-P1.pdf. Accessed June 3, 2013.
27. M. Brunner, P. Dehghanyar, and B. Seigfried Favourable dermal penetration of diclofenac after administration to the skin using a novel sprays gel formulation Br J Clin Pharmacol 60 2005 573 577
28. C. Rolf, B. Engstroem, and C. Beauchard Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy Rheumatology 38 1999 564 567
29. M. Domenikus, M. Nicolarkis, and R. Krotz Comparison of tissue and plasma levels of ibuprofen after oral and topical administration Drug Res 46 1996 1138 1143
30. M. Burian, I. Tegeder, and M. Seegel Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain Clin Pharmacol Ther 74 2003 113 120
31. A. Brewer, L. Pierchala, and J. Yanchick Gastrointestinal tolerability of diclofenac epolamine topical patch 1.3%: a pooled analysis of 14 clinical studies Postgrad Med 123 2011 168 176
32. S. Haroutiunian, D. Drennan, and A. Lipman Topical NSAID therapy for musculoskeletal pain Pain Med 11 2010 535 549
33. E. Prommer Levorphanol: the forgotten opioid Support Care Cancer 15 2007 259 264
34. K.E. Zorn, and J. Fudin Treatment of neuropathic pain: the role of unique opioid agents Practical Pain Management 11 2011 26 33
35. Levorphanol [package insert]. http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.Label-ApprovalHistory#apphist. Accessed July 15, 2013.
36. M. Rowbotham, L. Twilling, and P. Davies Oral opioid therapy for chronic peripheral and central neuropathic pain N Engl J Med 348 2003 1223 1232
37. L. Manchikanti, B. Fellows, and H. Ailinani Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective Pain Physician 13 2010 401 435
38. C. Jones, K. Mack, and L. Paulozzi Pharmaceutical overdose deaths, United States, 2010 JAMA 309 2013 657 659
39. S. Okie A flood of opioids, a rising tide of deaths N Engl J Med 363 2010 1981 1985
40. R. Dubner A call for more science, not more rhetoric, regarding opioids and neuropathic pain Pain 47 1991 1 2
41. S. Arner, and B. Meyerson Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain Pain 35 1988 365 367
42. P. Dellemijn Are opioids effective in relieving neuropathic pain? Pain 80 1999 453 462
43. Federation of State Medical Boards of the United States. Model policy for the use of controlled substances for the treatment of pain J Pain Palliat Care Pharmacother 19 2005 73 78
44. D.M Philips for the Joint Commission on Accreditation of Healthcare Organizations. JCAHO pain management standards unveiled JAMA 284 2000 428 429
45. T. Yamamura, K. Harada, and A. Okamura Is the site of action of ketamine anesthesia the N-methyl-d-aspartate receptor? Anesthesiology 72 1990 704 710
46. J. Clark, and G. Kalan Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient J Pain Symptom Manage 10 1995 310 314
47. M. Stringer, M. Makin, and J. Miles d-morphine, but not l-morphine, has low micromolar affinity for the non-competitive N-methyl-d-aspartate site in rat forebrain. Possible clinical implications for the management of neuropathic pain Neurosci Lett 295 2000 21 24
48. S. Qiu, T. Chen, and K. Koga An increase in synaptic NMDA receptors in the insular cortex contributes to neuropathic pain Sci Signal 6 2013 1 11
49. Y. Ho, J. Cheng, and L. Chiou Hypofunction of glutamatergic transmission in the periaqueductal gray contributes to nerve-injury induced neuropathic pain Neuroscience 33 2013 7825 7836
50. K. Trujillo, and H. Akil Inhibition of opiate tolerance by non-competitive N-methyl-d-aspartate receptor antagonists Brain Res 633 1994 178 188
51. B. Galer, D. Lee, and T. Ma MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multi-center, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance Pain 115 2005 284 295
52. E. Codd, R. Shank, and J. Schupsky Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception J Pharmacol Exp Ther 274 1995 1263 1270
53. J. Fudin for the CE Program of the University of Connecticut School of Pharmacy and Drug Topics. Opioid pain management: balancing risks and benefits Drug Topics 2011 46 58
54. Y. Wang, J. Li, and P. Huang Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cyclase superactivation is independent of agonist-induced phosphorylation, densensitization, internalization, and down regulation J Pharmacol Exp Ther 307 2003 1127 1134
55. L. Tive, K. Ginsberg, and C. Pick Kappa 3 receptors and levorphanol-induced analgesia Neuropharmacology 31 1992 851 856
56. A. Blake, G. Bot, and S. Li Differential agonist regulation of the human K-opioid receptor Neurochemistry 68 1997 1846 1852
57. R. Dixon, T. Crews, and C. Inturrisi Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain Res Commun Chem Pathol Pharmacol 41 1983 3 17
58. Practical pain management: opioid calculator. http://opioidcalculator. practicalpainmanagement.com. Accessed August 15, 2013.
59. Opioid chemistry. http://paindr.com/wp-content/uploads/2012/05/Opioid- Chemistry-09-2011.pdf. Accessed August 15, 2013.
60. J. Fudin, M.D. Marcoux, and J.A. Fudin A mathematical model for methadone conversion examined Practical Pain Manage 2012 46 51
61. Centers for Disease Control and Prevention. CDC features: prescription painkiller overdoses: methadone. http://www.cdc.gov/features/vitalsigns/ methadoneoverdoses/. Accessed July 4, 2013.
62. Centers for Disease Control and Prevention. Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6126a5.htm?s-cid=mm6126a5-w. Accessed July 4, 2013.
63. J. Fudin, D.V. Fontenelle, and H.R. Fudin Potential P-glycoprotein pharmacokinetic interaction of telaprevir with morphine or methadone J Pain Palliat Care Pharmacother 27 2013 261 267
64. Butrans [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2013/021306s016lbl.pdf. Accessed August 2, 2013.
65. Buprenex [package insert]. http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed August 2, 2013.
66. Subutex [package insert]. http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.Label-ApprovalHistory#labelinfo. Accessed August 2, 2013.
67. Suboxone [package insert]. http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.Label-ApprovalHistory#labelinfo. Accessed August 2, 2013.
68. K. Budd Old dog-new (ma)trix Br J Anaesth 90 2003 2 4
69. R. Likar Transdermal buprenorphine in the management of persistent pain: safety aspects Ther Clin Risk Manage 2 2006 115 125
70. M. Booth Opium: A History 1996 Simon & Schuster London, UK
71. R. Bullingham, J. McQuay, and A. Moore Buprenorphine kinetics Clin Pharmacol Ther 28 1980 667 672
72. A. Dahan, A. Yassen, and H. Bijl A comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans rats Br J Anaesth 94 2005 825 834
73. R. Boas, and J. Villiger Clinical actions of fentanyl and buprenorphine: the significance of receptor binding Br J Anaesth 57 1985 192 196
74. A. Yassen, E. Olofsen, and R. Romberg Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers Anesthesiology 104 2006 1232 1242
75. J. Pergolizzi, A. Aloisi, and A. Dahan Current knowledge of buprenorphine and its unique pharmacologic profile Pain Pract 10 2010 428 450
76. H. Evans, and S. Easthope Transdermal buprenorphine Drugs 63 2003 1999 2010 discussion 2011-2012
77. R. Kapil, A. Cipriano, and K. Friedman Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels J Pain Symptom Manage 46 2013 65 75
78. M. Tyers A classification of opiate receptors that mediate antinociception in animals Br J Pharmacol 68 1980 503 512
79. Buprenorphine transdermal patch: clinical expert report. Aachen, Germany: Grünenthal GmbH; 2000
80. K. Bohme Buprenorphine in a transdermal therapeutic system - a new option Clin Rheumatol 21 Suppl 1 2002 S13 S16
81. D. Jasinski, J. Pevnick, and J. Griffith Human pharmacology and abuse potential of the analgesic buprenorphine Arch Gen Psychiatry 35 1978 501 516
82. M. Greenwald, C. Johanson, and D. Moody Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers Neuropsychopharmacology 28 2003 2000 2009
83. D. Steiner, S. Sitar, and W. Wen Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study Pain Symptom Manage 42 2011 903 917
84. D. Steiner, C. Munera, and M. Hale Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study Pain 12 2011 1163 1173
85. I. James, C. O'Brien, and C. McDonald A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans Seven-Day Patches) with buprenorphine sublingual tablets (Temgesic®) in patients with osteoarthritis pain J Pain Symptom Manage 40 2010 266 278
86. A. Ojik, P. Jansen, and J. Brouwers Treatment of chronic pain in older people: evidenced-based choice of strong-acting opioids Drugs Aging 29 2012 615 625
87. V. Bach, M. Kamp-Jensen, and N. Jensen Buprenorphine and sustained release morphine - effect and side-effects in chronic use Pain Clinic 4 1991 87 93
88. L. Radbruch, and T.D.S. Buprenorphine use in daily practice, benefits for patients Int J Clin Pract Suppl 133 2003 19 22
89. A. Dahan, A. Yassen, and R. Romberg Buprenorphine induces ceiling in respiratory depression but not in analgesia Br J Anaesth 96 2006 627 632
90. N. Griessinger, R. Sittl, and R. Likar Transdermal buprenorphine in clinical practice - a post-marketing surveillance study in 13179 patients Curr Med Res 21 2005 1147 1156
91. Purdue Pharma. Initiation and titration guide. https://www.butrans.com/ images/pdf/InitationandTitration.pdf. Accessed July 27, 2013.
92. National Cancer Institute Pain (PDQ). Pharmacologic management. http://www.cancer.gov/cancertopics/pdq/supportivecare/pain/HealthProfessional/ Table3. Accessed July 28, 2013.
93. American Academy of Hospice and Palliative Medicine. Guidelines for prescribing opiates for hospice and palliative care patients. http://www.aahpm.org/pdf/equianalgesictable.pdf. Accessed August 10, 2013.
94. Detail-Document PL Equianalgesic Dosing of Opioids for Pain Management Pharmacist's Letter/Prescriber's Letter August 2012
95. J. Daitch, M. Frey, and D. Silver Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine Pain Physician 15 2012 ES59 ES66
96. M.L. McPherson Demystifying Opioid Conversion Calculations 2010 American Society of Health-System Pharmacists Bethesda, Md
97. R. Perkins Opioid analgesic comparison table http://paindr.com/wp- content/uploads/2012/05/OPIOID-ANALGESIC-COMPARISON-TABLE-Perkins.pdf Accessed August 10, 2013.
98. J. Pereira, P. Lawlor, and A. Vigano Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing J Pain Symptom Manage 22 2001 672 687
99. S. Mercandente, G. Porzio, and F. Fulfaro Switching from transdermal drugs: an observational "n of 1" study of fentanyl and buprenorphine J Pain Symptom Manage 34 2007 532 538
100. R. Sittl, R. Likar, and B. Nautrup Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and non-cancer pain: results of a prospective cohort study Clin Ther 27 2005 225 237
101. K. Shaw, and J. Fudin Evaluation and comparison of online equianalgesic opioid dose conversion calculators Practical Pain Manage 13 2013 61 66
102. Nucynta (tapentadol HCl) [package insert]. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2013/022304s007s008s009s011s012lbl.pdf. Accessed August 14, 2013.
103. Nucynta E.R. (tapentadol HCl) [package insert]. http://www.accessdata. fda.gov/drugsatfda-docs/label/2012/200533s001lbl.pdf. Accessed August 14, 2013.
104. K. Gohler, M. Brett, and J. Smit Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations Int J Clin Pharmacol Ther 51 2013 338 348
105. G. Carter, and M. Sullivan Antidepressants in pain management Curr Opin Invest Drugs 3 2002 454 458
106. T. Tzschentke, T. Christoph, and B. Kogel (-)-(1R,2R)-3-(3-Dimethylamino- 1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties J Pharmacol Exp Ther 323 2007 265 276
107. M. Max, S. Lynch, and J. Muir Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy N Engl J Med 326 1992 1250 1256
108. M. Briley Clinical experience with dual action antidepressants in different chronic pain syndromes Hum Psychopharmacol 19 2004 S21 S25
109. American Geriatric Society. American Geriatric Society updated Beers criteria for potentially inappropriate medication use in older adults J Am Geriatr Soc 60 2012 616 631
110. R. Davis, C. Hepfinger, and K. Sauer Retrospective evaluation of medication appropriateness and clinical pharmacist drug therapy recommendations for home-based primary care veterans Am J Geriatr Pharmacother 5 2007 40 47
111. R. Malseed, and F. Goldstein Enhancement of morphine analgesia by tricyclic antidepressants Neuropharmacology 18 1979 827 829
112. M. Botney, and H. Fields Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system Ann Neurol 13 1983 160 164
113. R. Raffa, E. Friderichs, and W. Reimann Opioid and non-opioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic J Pharmacol Exp Ther 260 1992 275 285
114. R. Raffa, E. Friderichs, and W. Reimann Complementary and synergistic antinociceptive interaction between enantiomers of tramadol J Pharmacol Exp Ther 267 1993 331 340
115. M. Frink, H. Hennies, and W. Englberger Influence of tramadol on neurotransmitter systems of the rat brain Arzneimittelforschung 46 1996 1029 1036
116. Ultram (tramadol HCl) [package insert]. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/020281s032s033lbl.pdf. Accessed August 15, 2013.
117. L. Poulsen, L. Arendt-Nielsen, and K. Brosen The hypoalgesic effect of tramadol in relation to CYP2D6 Clin Pharmacol Ther 60 1996 636 644
118. E. Boyer, and M. Shannon The serotonin syndrome [published correction appears in: N Engl J Med. 2007;356:2437] N Engl J Med 352 2005 1112 1120
119. C. Hartrick, I. Hove, and J. Stegmann Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10 day, phase III, randomized, double-blind, active- and placebo-controlled study Clin Ther 31 2009 260 271
120. S. Daniels, D. Upmalis, and A. Okamoto A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain Curr Med Res Opin 25 2009 765 776
121. M. Hale, D. Upmalis, and A. Okamoto Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study Curr Med Res Opin 25 2009 1095 1104
122. R. Buynak, D. Shapiro, and A. Okamoto Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study Exp Opin Pharmacother 11 2010 1787 1804
123. M. Afilalo, M. Etropolski, and B. Kuperwasser Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo-and active-controlled phase III study Clin Drug Invest 30 2010 489 505
124. S. Schwartz, M. Etropolski, and D. Shapiro Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial Curr Med Res Opin 27 2011 151 162
125. J. Wild, S. Grond, and B. Kuperwasser Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain Pain Pract 10 2010 416 427
126. R. Terlinden, J. Ossig, and F. Fliegert Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects Eur J Drug Metab Pharmacokinet 32 2007 163 169
127. S. Xu, J. Smit, and R. Lin Population pharmacokinetics of tapentadol immediate-release (IR) in healthy subjects and patients with moderate to severe pain Clin Pharmacokinet 49 2010 671 682
128. L. Pizzi, R. Toner, and K. Foley Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery Pharmacotherapy 32 2012 502 514
129. Dolophine [package insert]. http://dailymed.nlm.nih.gov/dailymed/lookup. cfm?setid=7a4840d6-98e3-4523-81a0-ef0b3a47d0c2. Accessed August 14, 2013.
130. M. Krantz, J. Martin, and B. Stimmel Clinical guidelines: QTc interval screening in methadone treatment Ann Intern Med 150 2009 387 395
131. G. Vorsanger, J. Xiang, and D. Biondi Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients Pain Res Manag 16 2011 245 251